Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

aTyr Pharma of San Diego and Hong Kong Plans $86 Million IPO

publication date: Apr 8, 2015
aTyr Pharma, a San Diego-Hong Kong clinical stage biotherapeutics company, filed to conduct an $86 million IPO on the NASDAQ exchange. The company develops Physiocrine-based therapeutics to address rare diseases. Its lead molecule, Resolaris, is currently in a Phase Ib/II trial in adult patients with facioscapulohumeral muscular dystrophy. Founded in 2005 by Paul Schimmel, PhD and Xiang-Lei Yang, PhD, the company has a Hong Kong subsidiary, Pangu BioPharma, which operates a laboratory at the Hong Kong University of Science and Technology. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital